Cargando…
小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342200/ https://www.ncbi.nlm.nih.gov/pubmed/29365406 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.016 |
_version_ | 1783555402115317760 |
---|---|
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7342200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73422002020-07-16 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2017-12 /pmc/articles/PMC7342200/ /pubmed/29365406 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.016 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 短篇论著 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 |
title | 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 |
title_full | 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 |
title_fullStr | 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 |
title_full_unstemmed | 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 |
title_short | 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 |
title_sort | 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 |
topic | 短篇论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342200/ https://www.ncbi.nlm.nih.gov/pubmed/29365406 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.016 |
work_keys_str_mv | AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī |